2-Oxo-1,2-dihydropyridine-3-carboximidamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Oxo-1,2-dihydropyridine-3-carboximidamide
• 英文别名: 2-oxo-1H-pyridine-3-carboximidamide
• 化学式: C₆H₇N₃O
• mdl: MFCD28391669
• 分子量: 137.14
• InChiKey: QZTKIXAQVKCAFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2014206150A1

  公开（公告）日：2014-12-31

  The present invention provides for compounds of formula (I). wherein Rx, Ry, Rx1, L1, G1, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物。其中Rx、Ry、Rx1、L1、G1、A1、A2、A3和A4具有规范中定义的任何值，并且其药学上可接受的盐，可用作治疗疾病和病症的药剂，包括炎症性疾病、癌症和艾滋病。还提供了由一种或多种式（I）的化合物组成的药物组合物。
• [EN] NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME BLOQUEURS DES CANAUX CALCIQUES
  申请人：ABBOTT LAB

  公开号：WO2010039947A1

  公开（公告）日：2010-04-08

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein Ar1, Ar2, L1, L2, n, R1, R4, X and Y are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中Ar1、Ar2、L1、L2、n、R1、R4、X和Y如规范中所定义。本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病和疾病的方法。
• Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
  申请人：Neurocrine Biosciences, Inc.

  公开号：US20030119878A1

  公开（公告）日：2003-06-26

  GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: 1 wherein A, R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

  GnRH受体拮抗剂被披露，对男性和女性的各种性激素相关疾病的治疗具有实用性。本发明的化合物具有以下结构：其中A、R1、R2、R3a、R3b、R4、R5、R6、R7和n如本文中所定义，包括立体异构体、前药和其药用盐。还披露了含有本发明化合物的组合物，与药用载体结合，以及与之相关的用于拮抗需要者中的促性腺激素释放激素的方法。
• Novel heteroaryl substituted piperidine derivatives which are L-CPT1 inhibitors
  申请人：Ackermann Jean

  公开号：US20070129544A1

  公开（公告）日：2007-06-07

  The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  这项发明涉及式(I)的新型替代哌啶衍生物，其中R1、R2、R3、R4、R5、R6、R7和X的定义如说明书和权利要求中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。
• [EN] NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] NOUVEAUX DÉRIVÉS TRIFLUOROMÉTHYL-OXADIAZOLES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2013080120A1

  公开（公告）日：2013-06-06

  The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4.

  该发明涉及一种新型三氟甲基-噁二唑衍生物的公式(I)，以及其药学上可接受的盐，其中所有变量均如规范中定义，其药物组合物，药物组合物及其作为药物的用途，特别用于通过抑制HDAC4治疗神经退行性疾病、肌肉萎缩或糖尿病/代谢综合征。